What is Zealand Pharma's post-Lyxumia future?
This article was originally published in Scrip
Zealand Pharma, with its partner Sanofi, is expecting a positive recommendation from the European Medicines Agency's CHMP for its type 2 diabetes treatment lixisenatide at any moment. The GLP-1 agonist is shaping up to be the only serious competitor to Novo Nordisk's hugely successful GLP-1 agonist Victoza (liraglutide).
You may also be interested in...
The UK's main reimbursement bodies made a series of decisions this week that were broadly favorable and largely focused on oncology medicines.
While troubled Valeant was divesting iNova to private equity investors, Novartis announced a pair of oncology-focused deals, out-licensing a brain cancer drug to Midatech and partnering with IBM Watson Health to optimize breast cancer treatment.
Astellas and Pfizer have amended the PROSPER trial protocol in a bid to position Xtandi ahead of Zytiga in the early stage prostate cancer market.